Medical Condition News

RSS

Attacks by specific type of immune cells cause inflammations of heart muscle

Scientists of the German Cancer Research Center, jointly with colleagues in the United States, have found out that inflammations of the heart muscle are caused by attacks of a specific type of immune cells. These immune cells attack the body's own tissue because during their maturation they did not have the chance to develop tolerance against a protein that is only found in the heart muscle.

30 Mar 2011

Stanford pediatrics receives Genzyme/ACMG award for biochemical genetic research

Anna-Kaisa Niemi, MD, Ph.D., a resident in Medical Genetics in the Department of Pediatrics, Division of Medical Genetics at the Stanford University Medical Center, in Stanford Calif., was honored as the 2011-2012 recipient of the Genzyme/American College of Medical Genetics Foundation Clinical Genetics Fellowship in Biochemical Genetics at the ACMG 2011 Annual Clinical Genetics Meeting in Vancouver, BC, Canada.

30 Mar 2011

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Oral antiplatelet therapy Effient has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention fter experiencing heart-related chest pain at rest or non-ST segment elevation myocardial infarction.

30 Mar 2011

Orthopedic surgeons prefer Genzyme's 3-cycle hyaluronic-acid in the U.S., Europe

According to a comprehensive global survey of orthopedic surgeons conducted by iData Research, the leading authority in medical device and pharmaceutical market research, orthopedic surgeons prefer 3-cycle hyaluronic-acid viscosupplementation treatment in the U.S., Europe and Latin Ameica, but are willing to try single-injection products such as Synvisc-One from Genzyme and MONOVISC from Anika Therapeutics.

30 Mar 2011

Prostate Oncology Specialists introduces new blog for patients

Prostate Oncology Specialists, Inc. announces the launch of the "Prostate Snatchers" blog. It features contributions from a medical oncologist, Mark Scholz MD, who specializes only in prostate cancer and a prostate cancer patient, Ralph H. Blum.

30 Mar 2011

Study examines plant-soil relationship and uptake of contaminants in ryegrass

The environmental concern is great when considering the role of toxic contaminants in the plant-soil relationship. Understanding plant's absorption and accumulation of these contaminants from the soil would be incredibly beneficial.

30 Mar 2011

Patients with dystonia can benefit from deep brain stimulation therapy

Patients suffering from dystonia, an uncommon yet potentially crippling movement disorder, get better results if they begin deep brain stimulation therapy sooner rather than later, according to an international study published in the March issue of the Journal of Neurology.

30 Mar 2011

Porter Adventist Hospital inaugurates new clinic to treat TIA

A transient ischemic attack is a form of minor stroke that can last just minutes, often without any lingering symptoms. But if left untreated, those who have one are at an estimated 25 percent greater risk of having another stroke or other complication within 90 days.

30 Mar 2011

Eya1 phosphatase controls fate of embryonic lung epithelial stem cells

Investigators at The Saban Research Institute of Children's Hospital Los Angeles have provided the first evidence that Eya1 protein phosphatase is a crucial regulator of the development of embryonic lung epithelial stem cells.

30 Mar 2011

Drugs' cost deters patients from taking heart medicine

For more than 5 million Americans with heart failure, a critical step to better health is taking the medications they're prescribed. But many patients fail to do so, putting themselves at greater risk of hospitalization and even death. To date, studies have not fully answered why patients fall short when it comes to taking heart medicine. In a study appearing in the April issue of Mayo Clinic Proceedings, Mayo Clinic researchers found the drugs' cost is one of the biggest deterrents.

30 Mar 2011

USPTO grants composition-of-matter patent to Zalicus 'Synavive' product

Zalicus Inc. announced today that it has been granted a composition-of-matter patent by the U.S. Patent and Trademark office covering its product candidate Synavive.

30 Mar 2011

BIOTRONIK completes patient enrollment in IN-TIME clinical trial to treat HF

BIOTRONIK SE & Co. KG, a leading manufacturer of cardiac devices, announced today that the last chronic heart failure patient was enrolled in IN-TIME at the Schwabing Clinic in Munich, Germany, with principle investigator Professor Stefan Sack, MD.

30 Mar 2011

Smoking withdrawal after liver transplantation may protect against neoplasia development

Spanish researchers have found that liver transplant recipients who quit smoking have a lower incidence of smoking-related malignancies than patients who keep smoking.

30 Mar 2011

Positive results from Vertex VX-770 Phase 3 trial against CF

Vertex Pharmaceuticals Incorporated today announced positive results from a 24-week analysis of the ongoing Phase 3 ENVISION study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

30 Mar 2011

Engineers create new microfluidic device that can detect cancer cells, HIV

A Harvard bioengineer and an MIT aeronautical engineer have created a new device that can detect single cancer cells in a blood sample, potentially allowing doctors to quickly determine whether cancer has spread from its original site.

30 Mar 2011

Researchers develop new drug for multiple cancer treatment

Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug called AT-406 with potential to treat multiple types of cancer.

30 Mar 2011

EC grants marketing authorization for GSK, Valeant's Trobalt to treat epilepsy

GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced today that the European Commission has granted marketing authorisation for Trobalt as an adjunctive treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.

30 Mar 2011

SHMT1 gene and folate deficiency increase risk for colon cancer

Offering a likely insight into how such cancers develop in humans - Cornell University researchers report they have identified a gene that increases the risk for colon cancer in laboratory mice when the animals' diets are deficient in folate.

30 Mar 2011

Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health that patient enrollment has started in a new clinical trial in patients with nonalcoholic steatohepatitis, which will evaluate Intercept's first-in-class farnesoid X receptor agonist obeticholic acid as a novel therapy for NASH.

30 Mar 2011

Study: Gene combinations may increase risk of hip osteoporosis in women

Women with osteoporosis in their hip suffer menopause two years earlier than healthy women, a study conducted at the University of Granada says. Additionally, although further study is required, researchers have found at least three genetic markers associated with osteoporosis in the hip in postmenopausal women.

30 Mar 2011